These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28584788)

  • 21. Multidrug-resistant tuberculosis in children: A practical update on epidemiology, diagnosis, treatment and prevention.
    Gaensbauer JT; Dash N; Verma S; Hall DJ; Adler-Shohet FC; Li G; Lee G; Dinnes L; Wendorf K
    J Clin Tuberc Other Mycobact Dis; 2024 Aug; 36():100449. PubMed ID: 38757115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
    Field SK
    Ther Adv Chronic Dis; 2015 Jul; 6(4):170-84. PubMed ID: 26137207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Grade III Severe QT Prolongation in an Indian Male on All-Oral Longer Regimen for Multidrug-Resistant Pulmonary Tuberculosis: World's First Case.
    Yadav S
    Cureus; 2022 Nov; 14(11):e31819. PubMed ID: 36579197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs and perspectives for new anti-tuberculosis regimens.
    Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB
    Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment.
    Lange C; Chesov D; Heyckendorf J; Leung CC; Udwadia Z; Dheda K
    Respirology; 2018 Jul; 23(7):656-673. PubMed ID: 29641838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
    Seaworth BJ; Griffith DE
    Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
    Muniyandi M; Ramachandran R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of multidrug-resistant tuberculosis in Thailand.
    Maranetra KN
    Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Antituberculosis Drugs: From Clinical Trial to Programmatic Use.
    Gualano G; Capone S; Matteelli A; Palmieri F
    Infect Dis Rep; 2016 Jun; 8(2):6569. PubMed ID: 27403268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.